molecules-logo

Journal Browser

Journal Browser

Antiviral Drug Development for the Treatment of Human Coronavirus

A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Medicinal Chemistry".

Deadline for manuscript submissions: closed (31 December 2021) | Viewed by 370

Special Issue Editors

Department of Medicinal Chemistry, College of Pharmaceutical Science, Soochow University, Suzhou 215021, China
Interests: gasotransmitter prodrugs; drug delivery; biorthogonal prodrug; antiviral drug development; host targeting antivirals
Special Issues, Collections and Topics in MDPI journals
Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
Interests: antiviral drug discovery; especially in influenza virus; coronavirus; hepatitis B virus; enterovirus 71
Key Laboratory of Human Disease Comparative Medicine, Chinese Ministry of Health, Beijing Key Laboratory for Animal Models of Emerging and Remerging Infectious Diseases, Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Comparative Medicine Center, Peking Union Medical College, Beijing, China
Interests: hand foot and mouth diseases, COVID-19; animal model and immunology

Special Issue Information

Dear Colleagues,

Viral infections still represent one major threat to human health. Although hundreds of viruses are known to be highly pathogenic, only less than ten of them can be treated with antiviral drugs in clinic. The coronavirus disease (COVID-19) pandemic has already claimed the lives of more than three million people worldwide and had a huge impact on everyone’s daily lifestyle. Although several types of vaccines have been approved with demonstrated efficacy in real-world study, concerns still remain. Chiefly, similar to other RNA viruses, high mutation rates will make SARS-Cov-2 so cunning as to evade the attack of antibodies. According to a recent study, more than 12,000 mutations in SARS-CoV-2 genomes have been identified. Therefore, developing antiviral agents against SARS-CoV-2 is still in high demand.

In this Special Issue, we aim to collect a series of high-quality reviews and research papers on antiviral drug development against human coronavirus. The scope includes but is not limited to structure-activity relationship studies, drug screening, drug repurposing, diagnosis and mechanism of action. In addition, we know that most of the institutions do not have the facility to conduct the activity test for highly pathogenic viruses such as SARS-Cov-2, so research papers dealing with any human coronavirus are also welcomed, especially the ones reporting broad-spectrum antiviral activities. 

Prof. Dr. Xingyue Ji
Prof. Dr. Yuhuan Li
Prof. Dr. Jiangning Liu
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • coronavirus
  • antiviral agents
  • structure-activity relationships
  • broad-spectrum antivirals
  • drug repurposing
  • drug resistance

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to TopTop